Nitromethaqualone

Nitromethaqualone, or 2-methyl-3-(2-nitrophenyl)-4(3H)-quinazolinone, is a compound of the quinazolinone class. Quinazolinone is a bicyclic structure containing a phenyl ring bound to another six-membered ring with two nitrogen members and a ketone group bound to R₄. In nitromethaqualone, this structure is substituted at R₂ with a methyl group and at R₃ with a nitro-substituted phenyl ring.

Nitromethaqualone is also known as 3,4-dihydro-2-methyl-3-(2-nitrophenyl)-4-oxoquinazoline. The nitro group presence distinguishes it from methaqualone and can alter its potency, duration of action, and safety profile.

Nitromethaqualone acts on the central nervous system by modulating the activity of GABA receptor sites, enhancing the inhibitory effects of the neurotransmitter GABA. This modulation leads to the sedative and hypnotic effects associated with the drug. However, specific studies on nitromethaqualone's pharmacodynamics suggest it may have a different binding affinity and efficacy at GABA_A receptors compared to methaqualone.

Despite its similarities to methaqualone, nitromethaqualone's distinct chemical structure may contribute to variations in its subjective and physiological effects. The presence of the nitro group could affect its metabolism, duration of action, and potential for adverse effects.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

• Erowid Experience Vaults: Methaqualone

Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

Overdose of nitromethaqualone can lead to seizures, coma, or death. Doses of over 300mg can be dangerous for first-time users. Depending on the user's individual tolerance, doses of about 8,000mg per day can be fatal, while some users on higher doses (up to 20,000mg) may survive.

Although the exact lethal dosage of nitromethaqualone has not been formally established, it is generally considered safe at appropriate dosages. Complications may arise when administered in excess or in combination with other depressants.

It is strongly recommended to use harm reduction practices when using this substance.

Illegally produced nitromethaqualone may contain other central nervous system depressants, such as benzodiazepines or fentanyl, posing additional risks.

Tolerance and addiction potential

Nitromethaqualone is extremely addictive. Tolerance to its sedative-hypnotic effects develops within a few days of repeated administration. After that, it takes about 3 - 7 days for tolerance to be reduced by half and 1 - 2 weeks to return to baseline (in the absence of further consumption). Nitromethaqualone presents cross-tolerance with all gabaergic depressants, meaning that after consuming nitromethaqualone, all compounds of the same class will have a reduced effect.

Abrupt discontinuation following regular dosing over several days can result in withdrawal symptoms such as increased anxiety and insomnia. Gradually reducing the dose over several days can lengthen the withdrawal period but reduce its intensity.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

• Depressants (1,4-Butanediol, 2M2B, alcohol, benzodiazepines, barbiturates, GHB/GBL, methaqualone, opioids) - This combination potentiates the muscle relaxation, amnesia, sedation, and respiratory depression caused by one another. At higher doses, it can lead to a sudden, unexpected loss of consciousness along with a dangerous amount of depressed respiration. There is also an increased risk of suffocating on one's vomit while unconscious. If nausea or vomiting occurs before a loss of consciousness, users should attempt to fall asleep in the recovery position or have a friend move them into it.
• Dissociatives - This combination can unpredictably potentiate the amnesia, sedation, motor control loss and delusions that can be caused by each other. It may also result in a sudden loss of consciousness accompanied by a dangerous degree of respiratory depression. If nausea or vomiting occurs before consciousness is lost, users should attempt to fall asleep in the recovery position or have a friend move them into it.
• Stimulants - Stimulants mask the sedative effect of depressants, which is the main factor most people use to gauge their level of intoxication. Once the stimulant effects wear off, the effects of the depressant will significantly increase, leading to intensified disinhibition, motor control loss, and dangerous black-out states. This combination can also potentially result in severe dehydration if one's fluid intake is not closely monitored. If choosing to combine these substances, one should strictly limit themselves to a pre-set schedule of dosing only a certain amount per hour until a maximum threshold has been reached.

• Responsible use
• Depressants
• Methaqualone
• GHB

• (Wikipedia)
• (PubChem)
• (NCBI)
• Quaaludes (Drugs.com)